Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase III, Multicenter, Randomized Trial of Maintenance Versus Observation After Achieving Clinical Response in Pts With Metastatic or Recurrent Breast Cancer Who Received 6 Cycles of Gemcitabine Plus Paclitaxel(GP) as 1st-line Chemotherapy

NCT00561119 is registered in ClinicalTrials.gov with Samsung Medical Center as lead sponsor.

NCT NCT00561119
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00561119 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase III, Multicenter, Randomized Trial of Maintenance Versus Observation After Achieving Clinical Response in Pts With Metastatic or Recurrent Breast Cancer Who Received 6 Cycles of Gemcitabine Plus Paclitaxel(GP) as 1st-line Chemotherapy
Lead sponsor
Samsung Medical Center
Phase
Phase 3
Overall status
Completed
Start date
May 31, 2007
Completion date
December 31, 2016
Enrollment
326 (actual)
Sites
15

Conditions

As the registry lists them; a condition with its own page is linked.

advanced breast cancer